Home » Healthcare » Pharmaceuticals » Alpha Emitters Market

Alpha Emitters Market By Type of Radionuclide (Radium (Ra-223), Actinium (Ac-225), Lead (Pb-212)) By Medical Applications (Prostate Cancer, Bone Metastases, Ovarian Cancer, Pancreatic Cancer, Endocrine Tumors, Other Medical Applications)-Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Published: | Report ID: 18749 | Report Format : PDF

Key Highlights of the Report

The global alpha emitters market is segmented by type of radionuclide, application and region. Since prostate cancer is becoming more common, the radium (Ra-223) segment is anticipated to dominate the alpha emitter market over the projection period. The FDA has approved the use of radium-223 to treat advanced prostate cancer. Due to the increasing burden of prostate cancer, the prostate cancer segment is anticipated to dominate the market over the forecast period, with North America leading the market growth.

The increase in the number of senior people and the burden of cancer on the world’s population are both contributing to the rapid growth of the alpha emitter market. Additionally, the market is anticipated to develop as more people adopt targeted alpha therapy (TAT) for cancer treatment and as awareness of TAT’s potential advantages rises. The alpha emitter market is likely to increase. However, obstacles, including a strict regulatory environment and a large capital investment requirement, are predicted to impede such expansion.

Nonetheless, the global alpha emitters market offers significant growth opportunities, including huge growth potential in the Asia Pacific region, and the increasing new developments in alpha emitters will further promote the market.\

Market Overview

The global alpha emitters market has witnessed steady growth in recent years and is expected to grow at a CAGR of 18.5% between 2023 and 2030. The market was valued at USD 370.9 million in 2022 and is expected to reach USD 1217.0 million in 2030.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

What Are The Main Drivers Of The Global Alpha Emitters Market?

The market is projected to rise due to rising consumer knowledge of the targeted alpha emitter’s potential advantages and a large patient population suffering from various malignancies, including ovarian, pancreatic, lymphoma, and melanoma. Additionally, alpha particles have an advantage in targeted therapy because of their unusually strong cell-killing potential. This is known as targeted anticancer or alpha therapy (TAT), which is increasingly used in cancer treatment.

What Are The Major Challenges Faced By The Global Alpha Emitters Market?

The rising burden/prevalence of cancer worldwide is one of the major reasons anticipated to boost the growth of the global alpha emitter market over the forecast period. For instance, the World Health Organisation (WHO) reports that cancer was one of the major causes of mortality globally in 2020, accounting for around ten million deaths, or about one in every six. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer.

What Are The Growth Opportunities In The Global Alpha Emitters Market?

The global alpha emitter market is projected to have significant growth prospects as people become more aware of the potential advantages of tailored alpha therapy. For instance, market participants and the general public are now more aware of the potential advantages of TAT in treating several chronic illnesses, such as cancer.

Executive Summary

Overview of the Global Alpha Emitters Market

The market is projected to develop as awareness of the potential benefits of targeted alpha emitters spreads and the number of cancer patients, particularly those with melanoma, lymphoma, pancreatic cancer, and ovarian cancer, increases. Additionally, alpha particles have a benefit in targeted therapy because of their very high cell-killing power. This is due to the growing usage of targeted anticancer or alpha therapy (TAT) in cancer treatment. This boosts the market for alpha emitters. Ovarian cancer-related deaths accounted for 4.4% of all cancer-related deaths among women in 2018, according to the National Centre for Biotechnology Information (NCBI). On the other hand, the market for alpha emitters is projected to see growth restrictions due to the strict rules and regulations for new product approvals and the high costs associated with research and development activities.

Alpha Emitters Market

Market Definition

Radioactive materials that decay after producing alpha particles are known as alpha emitters. They achieve optimal biodistribution and related dose distribution to acquire successful therapy without producing severe short- or long-term adverse effects. Due to their extremely high cell death rates, alpha particles in medical procedures are more destructive to tumor cells than beta particles. They consequently cause less damage to the nearby healthy tissues. Radium, lead, and bismuth are a few radionuclides used in the therapeutic process. Cancer treatment with alpha particles is probably one of the most challenging multidisciplinary projects. Alpha emitters achieve the necessary biodistribution and associated dosage distribution for efficient therapy with tolerable short- and long-term toxicity.

Market Insights

  • The global demand for alpha emitters was valued at USD 370.9 Million in 2022 and is expected to reach USD 1217.0 million in 2030, growing at a CAGR of 18.5% between 2023 and 2030.
  • The Radium (Ra-223) is the leading segment by type of radionuclide and held over 55% share in value in 2022, while the Actinium (Ac-225) segment is likely to exhibit a significant CAGR during the forecast period.
  • The prostate cancer segment governs the global demand for alpha emitters, holding a massive share of over 35% in 2022, and is expected to grow at a rapid CAGR.
  • The ovarian cancer segment will post the highest CAGR during the forecast period.
  • North America is fueling the growth of the alpha emitters industry with an over one-third share in 2022, while Asia Pacific and Europe collectively accounted for just under 50% share in 2022. Europe held over 22% share in 2022.
  • The huge growth potential in Asia Pacific is creating major opportunities in the market.

Segmentation by Type of Radionuclide

  • In 2022, the Radium (Ra-223) category dominated the alpha emitters market growth.
  • The Radium (Ra-223) segment is predicted to rule the alpha emitter market over the projection period due to the rising prevalence of prostate cancer. The FDA has authorized Radium-223 to treat advanced prostate cancer.
  • The lead (Pb-212) market is also anticipated to experience rapid expansion shortly due to the rising cancer burden globally. Lead Pb-212, which can be utilized in radioimmunotherapy, is crucial in the destruction of cancer cells.

Segmentation by Application

  • The prostate cancer segment dominated the alpha emitters market revenue in 2022 and is anticipated to increase quickly over 2022–2030.
  • Due to the increasing burden of prostate cancer, the Prostate Cancer Segment is anticipated to dominate the market over the forecast period. The second most prevalent type of cancer among males worldwide is prostate cancer. According to GLOBOCAN, there were approximately 1,414,259 cases of prostate cancer reported worldwide in 2020.
  • Due to the rising cancer burden, the bone metastases segment is expected to expand shortly. When cancer cells migrate from their primary site to a bone, this is known as bone metastasis. Almost all cancers can “metastasize” (spread) to the bones.

Segmentation by Region

  • North America is fuelling the growth of the alpha emitters industry with over one-third share in 2022.
  • Asia Pacific and Europe collectively account for just under 50% share in 2022, with Europe holding over 22% share in the same year.
  • The rest of the world, including Latin America, The Middle East, and Africa, contributes the remainder to the demand for adaptive strollers.

As cancer incidence rises, targeted anticancer/Alpha therapy is gaining popularity (TAT). Radioimmunotherapy using short-range, high-efficiency particles has promise for treating several chronic conditions. In targeted therapy, -particles’ capacity to kill cells is outstanding. Alpha emitter radiation therapy is very useful for treating chronic conditions.

The United States has the largest share of the market under consideration because of the existence of important market players and the rising frequency of infectious and chronic diseases. The country has the largest number of established foreign and domestic radioactive commercial raw materials suppliers. The increase in cancer cases and chronic neurological illnesses is the primary factor driving the market’s growth in the US. For instance, the Bayer AG product 223RaCl2 (Xofigo) was the first alpha-emitting radioisotope authorized in the US for palliative therapy of prostate cancer bone metastases via indirect physiological targeting.

It is anticipated that China’s market for alpha emitters will grow dramatically throughout the predicted timeframe. The Japanese Society of Nuclear Medicine (JSNM) was established in 1964. The main goal of JSNM is to promote the ethical creation of medical applications for radioactive materials and stable nuclides. The JSNM is interested in international collaboration for the development of nuclear medicine. Through its work both domestically and abroad, the JSNM advances society and medicine.

Targeted anticancer/alpha treatment (TAT) is getting increasingly popular as cancer incidence rises. Medical practitioners and scientific communities worldwide are becoming more aware of the potential benefits of using customized medications to treat certain conditions.

Increasing Cancer Prevalence

As cancer incidence rises, targeted anticancer/Alpha therapy is gaining popularity (TAT). Radioimmunotherapy using short-range, high-efficiency particles has promise for treating several chronic conditions. In targeted therapy, -particles’ capacity to kill cells is outstanding. Alpha emitter radiation therapy is very helpful for the treatment of chronic illnesses. Cancer is the second most common cause of death worldwide, behind heart disease. Alpha particles are a more direct treatment method, directly supplying energy to the DNA of cells and destroying chemical processes. It is being investigated for the treatment of different conditions as well as for the treatment of prostate cancer that has spread to the bones.

Greater attention is paid to disease diagnosis.

Many pharmaceutical and biotech companies are working to discover novel ways to diagnose this disease, some of which are currently in the last stages of clinical testing. Furthermore, improvements in diagnostic alternatives have sparked a better understanding of various cancer forms, enabling the creation of secure/efficient methods or equipment for cancer diagnosis. The global alpha emitter market is predicted to increase due to this tendency throughout the forecast period.

High capital expenditure will impede market expansion

The requirement for a significant financial expenditure impedes the expansion of the global market for alpha emitters. Due to their greater efficacy and reduced toxicity, particularly in the head and breast regions, the most common radionuclides, like Actinium-225 and Radium-223, are the most widely used in diagnostic and therapeutic procedures. However, these radionuclides are uncommon and require significant processing or chemical reaction investment. Additionally, removing carriers and contaminants is an expensive operation that raises the price of these products and inhibits market expansion.

Short Radiopharmaceutical Half-Life

An effective drug that is safe for human consumption that contains a radionuclide is known as a radiopharmaceutical. The preparation is suited for one or more diagnostic or therapeutic benefits since radionuclide is necessary for medicinal use. Half-lives are when certain radiopharmaceuticals lose half of their initial radioactivity. When employing radioactive drugs for diagnostic and therapeutic reasons, the three factors that should be considered are physical, biological, and effective half-lives. The amount of time required for both removal and decay to reduce the radioactivity level of a body organ or the entire body to exactly half its initial value is known as the effective half-life.

More knowledge of the potential advantages of targeted alpha therapy

Targeted anticancer/alpha treatment (TAT) is getting increasingly popular as cancer incidence rises. Medical practitioners and scientific communities worldwide are becoming more aware of the potential advantages of using customized medications to treat certain conditions. This increased awareness has led to a lot of research being done on focused therapy. The many components of this therapy are still being studied. Targeted alpha therapy is now being tested in several clinical trials and has shown the ability to treat disseminated and micro-metastatic malignancies without causing any severe or unmanageable effects. Because they offer a rapid and painless process, nuclear drugs thus represent a viable market for the early detection and imaging of many diseases.

Competitive Landscape

Key Players

The global alpha emitters market is highly competitive, with several key players. Some of the major players in the market and their market share are as follows:

  • Bayer AG
  • Fusion Pharmaceuticals
  • Alpha Tau Medical Ltd.
  • Telix Pharmaceuticals Ltd.
  • Orano Group (Orano Med)
  • NOVARTIS AG (Endocyte Inc.)
  • Actinium Pharmaceutical Inc.
  • IBA Radiopharma Solutions
  • RadioMedix Inc.
  • Others

To stay ahead, these companies focus on product innovation, expanding their distribution channels, and mergers and acquisitions. The major players in the global alpha emitters market constantly strive to stay ahead by introducing new products and innovations.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Summary of Key Findings

  • The growing prevalence of cancer patients is driving market growth
  • More knowledge on the potential advantages of targeted alpha therapy is promoting the market growth
  • Due to major players’ increasing regional investments, Asia Pacific is the fastest-growing alpha emitters market.

Future Outlook

  • Positive outlook for the global alpha emitters market with significant growth potential in the Asia Pacific region
  • Increasing adoption of alpha emitters in the medical and healthcare industry to drive growth
  • Key players to focus on product innovation, expanding market reach and maintaining competitive pricing to stay ahead.

Segmentation

  • By Type of Radionuclide
    • Radium (Ra-223)
    • Actinium (Ac-225)
    • Lead (Pb-212)
  • By Medical Applications
    • Prostate Cancer
    • Bone Metastases
    • Ovarian Cancer
    • Pancreatic Cancer
    • Endocrine Tumors
    • Other Medical Applications
  • By Region
  • North America
    • The US
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • The UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of the Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Data Modelling
1.3.2.1. Company Share Analysis Model
1.3.2.2. Revenue Based Modelling
1.3.3. Phase III – Primary Research
1.3.4. Research Limitations
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Alpha Emitters Market
2.2. Global Alpha Emitters Market, By Type of Radionuclide
2.3. Global Alpha Emitters Market, By Medical Applications
2.4. Global Alpha Emitters Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Alpha Emitters Market Value, 2017-2030, (US$ Mn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.2.3. Market Opportunities
3.2.4. Major Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Type of Radionuclide
3.5.2. Medical Applications
3.5.3. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Technology Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company market share of key players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Alpha Emitters Market, By Type of Radionuclide
7.1. Global Alpha Emitters Market Overview, by Type of Radionuclide
7.1.1. Global Alpha Emitters Market Revenue Share, By Type of Radionuclide, 2022 Vs 2030 (in %)
7.2. Radium (Ra-223)
7.2.1. Global Alpha Emitters Market, By Region, 2017-2030 (US$ Mn)
7.3. Actinium (Ac-225)
7.3.1. Global Alpha Emitters Market, By Region, 2017-2030 (US$ Mn)
7.4. Lead (Pb-212)
7.4.1. Global Alpha Emitters Market, By Region, 2017-2030 (US$ Mn)

8. Global Alpha Emitters Market, By Medical Applications
8.1. Global Alpha Emitters Market Overview, by Medical Applications
8.1.1. Global Alpha Emitters Market, By Medical Applications, 2022 vs 2030 (in %)
8.2. Prostate Cancer
8.2.1. Global Alpha Emitters Market, By Region, 2017-2030 (US$ Mn)
8.3. Bone Metastases
8.3.1. Global Alpha Emitters Market, By Region, 2017-2030 (US$ Mn)
8.4. Ovarian Cancer
8.4.1. Global Alpha Emitters Market, By Region, 2017-2030 (US$ Mn)
8.5. Pancreatic Cancer
8.5.1. Global Alpha Emitters Market, By Region, 2017-2030 (US$ Mn)
8.6. Endocrine Tumors
8.6.1. Global Alpha Emitters Market, By Region, 2017-2030 (US$ Mn)
8.7. Other Medical Applications
8.7.1. Global Alpha Emitters Market, By Region, 2017-2030 (US$ Mn)

9. Global Alpha Emitters Market, By Region
9.1. Global Alpha Emitters Market Overview, by Region
9.1.1. Global Alpha Emitters Market, By Region, 2022 vs 2030 (in%)
9.2. Type of Radionuclide
9.2.1. Global Alpha Emitters Market, By Type of Radionuclide, 2017-2030 (US$ Mn)
9.3. Medical Applications
9.3.1. Global Alpha Emitters Market, By Medical Applications, 2017-2030 (US$ Mn)

10. North America Alpha Emitters Market Analysis
10.1. North America Alpha Emitters Market, by Type of Radionuclide, 2017-2030(US$ Mn)
10.1.1. Overview
10.1.2. SRC Analysis
10.2. North America Alpha Emitters Market, by Medical Applications, 2017-2030(US$ Mn)
10.2.1. Overview
10.2.2. SRC Analysis
10.3. North America Alpha Emitters Market, by Country, 2017-2030 (US$ Mn)
10.3.1. North America Alpha Emitters Market, by Country, 2022 Vs 2030 (in%)
10.3.2. U.S.
10.3.2.1. U.S. Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
10.3.2.2. U.S. Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
10.3.2.3. U.S. Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)
10.3.3. Canada
10.3.3.1. Canada Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
10.3.3.2. Canada Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
10.3.3.3. Canada Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)
10.3.4. Mexico
10.3.4.1. Mexico Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
10.3.4.2. Mexico Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
10.3.4.3. Mexico Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)

11. Europe Alpha Emitters Market Analysis
11.1. Europe Alpha Emitters Market, by Type of Radionuclide, 2017-2030(US$ Mn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Europe Alpha Emitters Market, by Medical Applications, 2017-2030(US$ Mn)
11.2.1. Overview
11.2.2. SRC Analysis
11.3. Europe Alpha Emitters Market, by Country, 2017-2030 (US$ Mn)
11.3.1. Europe Alpha Emitters Market, by Country, 2022 Vs 2030 (in%)
11.3.2. Germany
11.3.2.1. Germany Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
11.3.2.2. Germany Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
11.3.2.3. Germany Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)
11.3.3. France
11.3.3.1. France Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
11.3.3.2. France Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
11.3.3.3. France Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)
11.3.4. UK
11.3.4.1. UK Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
11.3.4.2. UK Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
11.3.4.3. UK Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)
11.3.5. Italy
11.3.5.1. Italy Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
11.3.5.2. Italy Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
11.3.5.3. Italy Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)
11.3.6. Spain
11.3.6.1. Spain Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
11.3.6.2. Spain Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
11.3.6.3. Spain Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)
11.3.7. Rest of Europe
11.3.7.1. Rest of Europe Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
11.3.7.2. Rest of Europe Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
11.3.7.3. Rest of Europe Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)

12. Asia Pacific Alpha Emitters Market Analysis
12.1. Asia Pacific Alpha Emitters Market, by Type of Radionuclide, 2017-2030(US$ Mn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Asia Pacific Alpha Emitters Market, by Medical Applications, 2017-2030(US$ Mn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Asia Pacific Alpha Emitters Market, by Country, 2017-2030 (US$ Mn)
12.3.1. Asia Pacific Alpha Emitters Market, by Country, 2022 Vs 2030 (in%)
12.3.2. China
12.3.2.1. China Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
12.3.2.2. China Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
12.3.2.3. China Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)
12.3.3. Japan
12.3.3.1. Japan Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
12.3.3.2. Japan Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
12.3.3.3. Japan Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)
12.3.4. India
12.3.4.1. India Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
12.3.4.2. India Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
12.3.4.3. India Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)
12.3.5. South Korea
12.3.5.1. South Korea Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
12.3.5.2. South Korea Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
12.3.5.3. South Korea Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)
12.3.6. South-East Asia
12.3.6.1. South-East Asia Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
12.3.6.2. South-East Asia Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
12.3.6.3. South-East Asia Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)
12.3.7. Rest of Asia Pacific
12.3.7.1. Rest of Asia Pacific Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
12.3.7.2. Rest of Asia Pacific Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
12.3.7.3. Rest of Asia Pacific Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)

13. Latin America Alpha Emitters Market Analysis
13.1. Latin America Alpha Emitters Market, by Type of Radionuclide, 2017-2030(US$ Mn)
13.1.1. Overview
13.1.2. SRC Analysis
13.2. Latin America Alpha Emitters Market, by Medical Applications, 2017-2030(US$ Mn)
13.2.1. Overview
13.2.2. SRC Analysis
13.3. Latin America Alpha Emitters Market, by Country, 2017-2030 (US$ Mn)
13.3.1. Latin America Alpha Emitters Market, by Country, 2022 Vs 2030 (in%)
13.3.2. Brazil
13.3.2.1. Brazil Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
13.3.2.2. Brazil Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
13.3.2.3. Brazil Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)
13.3.3. Argentina
13.3.3.1. Argentina Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
13.3.3.2. Argentina Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
13.3.3.3. Argentina Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)
13.3.4. Rest of Latin America
13.3.4.1. Rest of Latin America Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
13.3.4.2. Rest of Latin America Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
13.3.4.3. Rest of Latin America Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)

14. Middle East and Africa Alpha Emitters Market Analysis
14.1. Middle East and Africa Alpha Emitters Market, by Type of Radionuclide, 2017-2030(US$ Mn)
14.1.1. Overview
14.1.2. SRC Analysis
14.2. Middle East and Africa Alpha Emitters Market, by Medical Applications, 2017-2030(US$ Mn)
14.2.1. Overview
14.2.2. SRC Analysis
14.3. Middle East and Africa Alpha Emitters Market, by Country, 2017-2030 (US$ Mn)
14.3.1. Middle East and Africa Alpha Emitters Market, by Country, 2022 Vs 2030 (in%)
14.3.2. GCC Countries
14.3.2.1. GCC Countries Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
14.3.2.2. GCC Countries Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
14.3.2.3. GCC Countries Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)
14.3.3. South Africa
14.3.3.1. South Africa Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
14.3.3.2. South Africa Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
14.3.3.3. South Africa Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)
14.3.4. Rest of Middle East and Africa
14.3.4.1. Rest of Middle East and Africa Alpha Emitters Market Estimates and Forecast, 2017-2030 (US$ Mn)
14.3.4.2. Rest of Middle East and Africa Alpha Emitters, By Type of Radionuclide, 2017-2030 (US$ Mn)
14.3.4.3. Rest of Middle East and Africa Alpha Emitters, By Medical Applications, 2017-2030 (US$ Mn)

15. Company Profiles
15.1. Bayer AG
15.1.1. Company Overview
15.1.2. Medical Applicationss/Services Portfolio
15.1.3. Geographical Presence
15.1.4. Financial Summary
15.1.4.1. Market Revenue and Net Profit (2019-2022)
15.1.4.2. Business Segment Revenue Analysis
15.1.4.3. Geographical Revenue Analysis
15.2. Alpha Tau Medical Ltd.
15.3. Fusion Pharmaceuticals
15.4. Telix Pharmaceuticals Ltd.
15.5. Orano Group (Orano Med)
15.6. NOVARTIS AG (Endocyte Inc.)
15.7. Actinium Pharmaceutical Inc.

List of Figures
FIG. 1 Global Alpha Emitters Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Alpha Emitters Market Segmentation
FIG. 4 Global Alpha Emitters Market, by Type of Radionuclide, 2022 (US$ Mn)
FIG. 5 Global Alpha Emitters Market, by Medical Applications, 2022 (US$ Mn)
FIG. 6 Global Alpha Emitters Market, by Geography, 2022 (US$ Mn)
FIG. 7 Attractive Investment Proposition, by Type of Radionuclide, 2022
FIG. 8 Attractive Investment Proposition, by Medical Applications, 2022
FIG. 9 Attractive Investment Proposition, by Geography, 2022
FIG. 10 Global Market Share Analysis of Key Alpha Emitters Market Manufacturers, 2022
FIG. 11 Global Market Positioning of Key Alpha Emitters Market Manufacturers, 2022
FIG. 12 Global Alpha Emitters Market Value Contribution, By Type of Radionuclide, 2022 & 2030 (Value %)
FIG. 13 Global Alpha Emitters Market, by Radium (Ra-223), Value, 2017-2030 (US$ Mn)
FIG. 14 Global Alpha Emitters Market, by Actinium (Ac-225), Value, 2017-2030 (US$ Mn)
FIG. 15 Global Alpha Emitters Market, by Lead (Pb-212), Value, 2017-2030 (US$ Mn)
FIG. 16 Global Alpha Emitters Market Value Contribution, By Medical Applications, 2022 & 2030 (Value %)
FIG. 17 Global Alpha Emitters Market, by Prostate Cancer, Value, 2017-2030 (US$ Mn)
FIG. 18 Global Alpha Emitters Market, by Bone Metastases, 2017-2030 (US$ Mn)
FIG. 19 Global Alpha Emitters Market, by Ovarian Cancer, 2017-2030 (US$ Mn)
FIG. 20 Global Alpha Emitters Market, by Pancreatic Cancer, 2017-2030 (US$ Mn)
FIG. 21 Global Alpha Emitters Market, by Endocrine Tumors, 2017-2030 (US$ Mn)
FIG. 22 Global Alpha Emitters Market, by Other Medical Applications, 2017-2030 (US$ Mn)
FIG. 23 North America Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 24 U.S. Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 25 Canada Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 26 Europe Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 27 Germany Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 28 France Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 29 U.K. Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 30 Italy Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 31 Spain Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 32 Rest of Europe Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 33 Asia Pacific Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 34 China Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 35 Japan Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 36 India Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 37 South Korea Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 38 South-East Asia Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 39 Rest of Asia Pacific Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 40 Latin America Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 41 Brazil Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 42 Mexico Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 43 Rest of Latin America Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 44 Middle East & Africa Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 45 GCC Countries Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 46 South Africa Alpha Emitters Market, 2017-2030 (US$ Mn)
FIG. 47 Rest of Middle East and Africa Alpha Emitters Market, 2017-2030 (US$ Mn)

List of Tables
TABLE 1 Market Snapshot: Global Alpha Emitters Market
TABLE 2 Global Alpha Emitters Market: Market Drivers Impact Analysis
TABLE 3 Global Alpha Emitters Market: Market Restraints Impact Analysis
TABLE 4 Global Alpha Emitters Market, by Competitive Benchmarking, 2022
TABLE 5 Global Alpha Emitters Market, by Geographical Presence Analysis, 2022
TABLE 6 Global Alpha Emitters Market, by Key Strategies Analysis, 2022
TABLE 7 Global Alpha Emitters Market, by Radium (Ra-223), By Region, 2017-2022 (US$ Mn)
TABLE 8 Global Alpha Emitters Market, by Radium (Ra-223), By Region, 2023-2030 (US$ Mn)
TABLE 9 Global Alpha Emitters Market, by Actinium (Ac-225), By Region, 2017-2022 (US$ Mn)
TABLE 10 Global Alpha Emitters Market, by Actinium (Ac-225), By Region, 2023-2030 (US$ Mn)
TABLE 11 Global Alpha Emitters Market, by Lead (Pb-212), By Region, 2017-2022 (US$ Mn)
TABLE 12 Global Alpha Emitters Market, by Lead (Pb-212), By Region, 2023-2030 (US$ Mn)
TABLE 13 Global Alpha Emitters Market, by Prostate Cancer, By Region, 2017-2022 (US$ Mn)
TABLE 14 Global Alpha Emitters Market, by Prostate Cancer, By Region, 2023-2030 (US$ Mn)
TABLE 15 Global Alpha Emitters Market, by Bone Metastases, By Region, 2017-2022 (US$ Mn)
TABLE 16 Global Alpha Emitters Market, by Bone Metastases, By Region, 2023-2030 (US$ Mn)
TABLE 17 Global Alpha Emitters Market, by Ovarian Cancer, By Region, 2017-2022 (US$ Mn)
TABLE 18 Global Alpha Emitters Market, by Ovarian Cancer, By Region, 2023-2030 (US$ Mn)
TABLE 19 Global Alpha Emitters Market, by Pancreatic Cancer, By Region, 2017-2022 (US$ Mn)
TABLE 20 Global Alpha Emitters Market, by Pancreatic Cancer, By Region, 2023-2030 (US$ Mn)
TABLE 21 Global Alpha Emitters Market, by Endocrine Tumors, By Region, 2017-2022 (US$ Mn)
TABLE 22 Global Alpha Emitters Market, by Endocrine Tumors, By Region, 2023-2030 (US$ Mn)
TABLE 23 Global Alpha Emitters Market, by Other Medical Applications, By Region, 2017-2022 (US$ Mn)
TABLE 24 Global Alpha Emitters Market, by Other Medical Applications, By Region, 2023-2030 (US$ Mn)
TABLE 25 Global Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 26 Global Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 27 Global Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 28 Global Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 29 Global Alpha Emitters Market, by Region, 2017-2022 (US$ Mn)
TABLE 30 Global Alpha Emitters Market, by Region, 2023-2030 (US$ Mn)
TABLE 31 North America Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 32 North America Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 33 North America Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 34 North America Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 35 North America Alpha Emitters Market, by Country, 2017-2022 (US$ Mn)
TABLE 36 North America Alpha Emitters Market, by Country, 2023-2030 (US$ Mn)
TABLE 37 United States Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 38 United States Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 39 United States Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 40 United States Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 41 Canada Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 42 Canada Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 43 Canada Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 44 Canada Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 45 Mexico Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 46 Mexico Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 47 Mexico Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 48 Mexico Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 49 Europe Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 50 Europe Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 51 Europe Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 52 Europe Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 53 Europe Alpha Emitters Market, by Country, 2017-2022 (US$ Mn)
TABLE 54 Europe Alpha Emitters Market, by Country, 2023-2030 (US$ Mn)
TABLE 55 Germany Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 56 Germany Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 57 Germany Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 58 Germany Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 59 France Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 60 France Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 61 France Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 62 France Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 63 United Kingdom Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 64 United Kingdom Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 65 United Kingdom Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 66 United Kingdom Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 67 Italy Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 68 Italy Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 69 Italy Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 70 Italy Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 71 Spain Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 72 Spain Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 73 Spain Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 74 Spain Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 75 Rest of Europe Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 76 Rest of Europe Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 77 Rest of Europe Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 78 Rest of Europe Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 79 Asia Pacific Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 80 Asia Pacific Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 81 Asia Pacific Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 82 Asia Pacific Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 83 China Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 84 China Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 85 China Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 86 China Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 87 Japan Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 88 Japan Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 89 Japan Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 90 Japan Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 91 India Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 92 India Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 93 India Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 94 India Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 95 South Korea Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 96 South Korea Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 97 South Korea Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 98 South Korea Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 99 South-East Asia Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 100 South-East Asia Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 101 South-East Asia Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 102 South-East Asia Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 103 Rest of Asia Pacific Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 104 Rest of Asia Pacific Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 105 Rest of Asia Pacific Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 106 Rest of Asia Pacific Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 107 Latin America Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 108 Latin America Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 109 Latin America Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 110 Latin America Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 111 Brazil Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 112 Brazil Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 113 Brazil Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 114 Brazil Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 115 Argentina Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 116 Argentina Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 117 Argentina Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 118 Argentina Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 119 Rest of Latin America Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 120 Rest of Latin America Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 121 Rest of Latin America Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 122 Rest of Latin America Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 123 Middle East and Africa Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 124 Middle East and Africa Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 125 Middle East and Africa Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 126 Middle East and Africa Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 127 GCC Countries Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 128 GCC Countries Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 129 GCC Countries Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 130 GCC Countries Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 131 South Africa Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 132 South Africa Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 133 South Africa Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 134 South Africa Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)
TABLE 135 Rest of Middle East and Africa Alpha Emitters Market, by Type of Radionuclide, 2017-2022 (US$ Mn)
TABLE 136 Rest of Middle East and Africa Alpha Emitters Market, by Type of Radionuclide, 2023-2030 (US$ Mn)
TABLE 137 Rest of Middle East and Africa Alpha Emitters Market, by Medical Applications, 2017-2022 (US$ Mn)
TABLE 138 Rest of Middle East and Africa Alpha Emitters Market, by Medical Applications, 2023-2030 (US$ Mn)

Frequently Asked Questions

What is the current size of the global alpha emitters market?

The global alpha emitters market was valued at USD 370.9 Million in 2022.

What is the expected growth rate of the alpha emitters market between 2023 and 2030?

The alpha emitters market is expected to grow at a CAGR of 18.5% between 2023 and 2030, reaching USD 1217.0 Million in 2030.

Which segment is leading the market share in terms of type of radionuclide?

Radium is the leading segment by type of radionuclide, holding over 55% share in value in 2022.

Which medical application segment governs the world’s demand for alpha emitters?

The prostate cancer segment governs the world’s demand for alpha emitters, holding a massive share of over 35% in 2022.

Which segment is expected to post the highest CAGR during the forecast period?

The bone Metastases segment will post the highest CAGR during the forecast period.

Which region is fueling the growth of the alpha emitters industry?

North America is fueling the growth of the alpha emitters industry, with an over one-third share in 2022.

Who are the major players in the global alpha emitters market?

Top players are Bayer AG, Alpha Tau Medical Ltd., Fusion Pharmaceuticals, Telix Pharmaceuticals Ltd., and Orano Group.

What are the major market drivers of the alpha emitters industry?

The growing prevalence of cancer patients is the major market driver.

What are the major market restraints of the alpha emitters industry?

High capital expenditure is the major market restraint.

What are the major market opportunities in the alpha emitters industry?

Increasing awareness regarding the advantages of alpha emitters.

Antineoplastic Agents Market

Published:
Report ID: 36065

US Retail Pharmacy Market

Published:
Report ID: 32801

OTC Vitamins Dietary Supplements Market

Published:
Report ID: 35994

Liposomes Market

Published:
Report ID: 35888

UK Iron Supplement Market

Published:
Report ID: 35709

U.S. Iron Supplement Market

Published:
Report ID: 35688

Malignant Ascites Market

Published:
Report ID: 11184

Middle East and Africa In-Vitro Fertilization (IVF) Market

Published:
Report ID: 35578

Chronic Myeloid Leukemia (CML) Treatment Market

Published:
Report ID: 2939

Combination Therapies In Aesthetics Market

Published:
Report ID: 35434

CAR T-Cell Therapy Market

Published:
Report ID: 2051

OTC Cough Cold And Allergy Medicine Market

Published:
Report ID: 20062

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN